These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9415889)

  • 21. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
    Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
    Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.
    Spooner RA; Friedlos F; Maycroft K; Stribbling SM; Roussel J; Brueggen J; Stolz B; O'Reilly T; Wood J; Matter A; Marais R; Springer CJ
    Br J Cancer; 2003 May; 88(10):1622-30. PubMed ID: 12771932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
    Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
    Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
    Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS
    NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
    Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
    J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
    Benouchan M; Do Nascimento F; Perret GY; Colombo BM
    Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells.
    Wu Z; Shah A; Patel N; Yuan X
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5108-12. PubMed ID: 20674353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutamyl hydrolase: properties and pharmacologic impact.
    Galivan J; Ryan T; Rhee M; Yao R; Chave K
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):33-7. PubMed ID: 10598552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.
    Wu K; Eng E; Knox R; Chen S
    Arch Biochem Biophys; 2001 Jan; 385(1):203-8. PubMed ID: 11361019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
    Aldughaim MS; Alsaffar F; Barker MD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
    Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
    J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
    Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
    Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.